The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus
Autor: | Tamar Aprahamian, Chris Andry, Christophe Richez, Zachary Weitzner, Ian R. Rifkin, Rocco J. Richards, Pierre Duffau |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2013 |
Předmět: |
Apolipoprotein E
Mouse Lupus nephritis lcsh:Medicine Cardiovascular Eating Mice 0302 clinical medicine immune system diseases Lupus Erythematosus Systemic skin and connective tissue diseases lcsh:Science 0303 health sciences Nephritis Multidisciplinary Systemic lupus erythematosus Animal Models 3. Good health Disease Progression Medicine medicine.symptom Immunosuppressive Agents Research Article medicine.drug Fas Ligand Protein Clinical Research Design Immunology Inflammation Systemic Lupus Erythematosus Mycophenolic acid Autoimmune Diseases 03 medical and health sciences Apolipoproteins E Model Organisms Immune system Rheumatology medicine Animals Humans Animal Models of Disease Lymphatic Diseases Biology Autoantibodies 030304 developmental biology 030203 arthritis & rheumatology Lupus Erythematosus business.industry Body Weight lcsh:R Immunity Autoantibody Mycophenolic Acid Atherosclerosis medicine.disease Disease Models Animal Splenomegaly Clinical Immunology lcsh:Q business |
Zdroj: | PLoS ONE, Vol 8, Iss 4, p e61042 (2013) PLoS ONE |
ISSN: | 1932-6203 |
Popis: | Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is characterized by autoantibody production and inflammatory disease involving multiple organs. Premature atherosclerosis is a common complication of SLE and results in substantial morbidity and mortality from cardiovascular disease (CVD). The reasons for the premature atherosclerosis in SLE are incompletely understood, although chronic inflammation is thought to play an important role. There is currently no known preventative treatment of premature atherosclerosis in SLE. Mycophenolate mofetil (MMF) is an immunosuppressive agent that is commonly used for treatment of patients with SLE. In order to study the impact of this drug on murine lupus disease including premature atherosclerosis development, we treated gld.apoE(-/-) mice, a model of SLE and accelerated atherosclerosis, with MMF. We maintained seven-week old gld.apoE(-/-) mice on a high cholesterol Western diet with or without MMF. After 12 weeks on diet, mice receiving MMF showed decreased atherosclerotic lesion area compared to the control group. MMF treatment also improved the lupus phenotype, indicated by a significant decrease circulating autoantibody levels and ameliorating lupus nephritis associated with this model. This data suggests that the effects of MMF on the immune system may not only be beneficial for lupus, but also for inflammation driving lupus-associated atherosclerosis. |
Databáze: | OpenAIRE |
Externí odkaz: |